Global Partnerships Leverage existing joint venture with Queensland Bauxite for Australia and Asia, and the Ontario-based collaboration with Emblem Corp to accelerate cross-border expansion and diversify market channels across wellness-focused cannabinoid products.

Patent Driven Capitalize on a solid IP position with 13 patents pending to differentiate offerings in hard pill cannabinoid formulations and protect shelf-stable, precise dosages that appeal to medical providers and pharmacists.

Regulatory Readiness Two products have earned Health Canada NPN numbers, enabling near-term entry into Canadian medical markets; target healthcare systems, clinics, and pharmacy networks seeking discrete, accurate dosing options.

Therapeutic Pill Line Promote hard pill delivery as a premier solution for medical oral administration, highlighting safety, discreteness, and reliability to clinicians, long-term care facilities, and compounding pharmacies exploring cannabinoid therapies.

Strategic Leadership Utilize recent leadership appointments and strategic consultants to accelerate market outreach, channel partnerships, and eCommerce-enabled sales efforts aimed at both medical and wellness segments.